Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination
(C) 2022 The Authors
2022
2022-06-24 13:02:16
1033
onkološko zdravljenje, imunogenost, osnovno cepljenje mRNA, čvrsti tumorji, anticancer treatment, immunogenicity, mRNA-based vaccination, solid cancer
Future Medicine
Urška
Janžič
70
Urška
Bidovec
70
Katja
Mohorčič
70
Loredana
Mrak
70
Nina
Fokter Dovnik
70
Marija
Ivanović
70
Maja
Ravnik
70
Marina
Čakš
70
Erik
Škof
70
Jerneja
Debeljak
70
Peter
Korošec
70
Matija
Rijavec
70
UDK
4
616-006
ISSN pri članku
9
1479-6694
DOI
15
10.2217/fon-2022-0148
COBISS_ID
3
111378179
RAZ_Janzic_Urska_i2022.pdf
2126590
Predstavitvena datoteka
2022-06-24 13:08:53